PF-Atlas › Clinical Trials › NCT05530278
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Galicaftor · Phase 1
Registry ID
NCT05530278
Phase
Phase 1
Status
Completed
Drug / intervention
Galicaftor
Sponsor
AbbVie
Start
2022-09-20
About this trial
Galicaftor is evaluated in NCT05530278, a Phase 1 idiopathic pulmonary fibrosis study sponsored by AbbVie. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05530278 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.